HRP20192010T1 - Muskarinski antagonisti i njihove kombinacije za liječenje bolesti dišnih puteva kod konja - Google Patents
Muskarinski antagonisti i njihove kombinacije za liječenje bolesti dišnih puteva kod konja Download PDFInfo
- Publication number
- HRP20192010T1 HRP20192010T1 HRP20192010TT HRP20192010T HRP20192010T1 HR P20192010 T1 HRP20192010 T1 HR P20192010T1 HR P20192010T T HRP20192010T T HR P20192010TT HR P20192010 T HRP20192010 T HR P20192010T HR P20192010 T1 HRP20192010 T1 HR P20192010T1
- Authority
- HR
- Croatia
- Prior art keywords
- lama
- halogen
- alkyl
- pharmaceutically acceptable
- alkyloxy
- Prior art date
Links
- 241000283086 Equidae Species 0.000 title claims 5
- 208000023504 respiratory system disease Diseases 0.000 title claims 4
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 title 1
- 239000003149 muscarinic antagonist Substances 0.000 title 1
- 229940110339 Long-acting muscarinic antagonist Drugs 0.000 claims 30
- 229910052736 halogen Chemical group 0.000 claims 15
- 150000002431 hydrogen Chemical class 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- 150000002367 halogens Chemical group 0.000 claims 9
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims 7
- 229960003728 ciclesonide Drugs 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 6
- 125000002091 cationic group Chemical group 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- 101100127662 Mus musculus Lama1 gene Proteins 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 239000003862 glucocorticoid Substances 0.000 claims 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
- 208000018569 Respiratory Tract disease Diseases 0.000 claims 3
- 150000001450 anions Chemical class 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 230000003287 optical effect Effects 0.000 claims 3
- 229940121786 Beta 2 adrenoreceptor agonist Drugs 0.000 claims 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 2
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 2
- 239000000048 adrenergic agonist Substances 0.000 claims 2
- 229960004436 budesonide Drugs 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 239000012669 liquid formulation Substances 0.000 claims 2
- 229960000257 tiotropium bromide Drugs 0.000 claims 2
- 208000000884 Airway Obstruction Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 230000003044 adaptive effect Effects 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229940125389 long-acting beta agonist Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940071648 metered dose inhaler Drugs 0.000 claims 1
- 238000009304 pastoral farming Methods 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
- A61K35/06—Mineral oils, e.g. paraffinic oils or aromatic oils based on aromatic hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2250/00—Specially adapted for animals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (12)
1. Dugodjelujući muskarinski antagonist (LAMA – engl. long-acting muscarinic antagonist) ili njegova farmaceutski prihvatljiva sol od kationa, naznačen time, da
se upotrebljava u postupku liječenja bolesti dišnih puteva kod jednokopitara, poželjno konja,
pri čemu je LAMA spoj opće formule:
u kojoj
A označava dvostruko vezanu skupinu odabranu između sljedećih:
X- označava anion s jednostrukim negativnim nabojem;
R1 i R2 označavaju C1-C4-alkil koji može biti opcionalno supstituiran s hidroksi
ili halogenom;
R3, R4, R5 i R6, koji mogu biti isti ili različiti, označavaju vodik, C1-C4-alkil,
C1-C4-alkiloksi, hidroksi, CF3, CN, NO2 ili halogen;
R7 označava vodik, C1-C4-alkil, C1-C4-alkiloksi, C1-C4-alkilen-halogen, halogen-C1-C4-alkiloksi, C1-C4-alkilen-OH, CF3, -C1-C4-alkilen-C1-C4-alkiloksi,
-O-COC1-C4-alkil, OCOC1-C4-alkil-halogen, -O-COCF3 ili halogen,
opcionalno u obliku njihovih pojedinačnih optičkih izomera, mješavina njihovih pojedinačnih enantiomera ili racemata,
dok, u slučaju da A označava
tada R1 i R2 označavaju metil i
R3, R4, R5 i R6 označavaju vodik,
a R7 ne može biti također vodik,
poželjno, LAMA je spoj formule (LAMA 1):
2. Dugodjelujući muskarinski antagonist (LAMA) ili njegova farmaceutski prihvatljiva sol od kationa, ili farmaceutski pripravak koji sadrži LAMA ili njegovu farmaceutski prihvatljivu sol od kationa, naznačen time, da se u kombinaciji s glukokortikoidom kao što je ciklesonid ili budesonid ili s farmaceutskim pripravkom koji sadrži ciklesonid ili njegovu farmaceutski prihvatljivu sol, upotrebljava kao lijek kod jednokopitara kao što je konj,
pri čemu je LAMA spoj opće formule:
u kojoj
A označava dvostruko vezanu skupinu odabranu od sljedećih:
X- označava anion s jednostrukim negativnim nabojem;
R1 i R2 označavaju C1-C4-alkil koji može biti opcionalno supstituiran s hidroksi ili halogenom;
R3, R4, R5 i R6, koji mogu biti isti ili različiti, označavaju vodik, C1-C4-alkil,
C1-C4-alkiloksi, hidroksi, CF3, CN, NO2 ili halogen;
R7 označava vodik, C1-C4-alkil, C1-C4-alkiloksi, C1-C4-alkilen-halogen, halogen-C1-C4-alkiloksi, C1-C4-alkilen-OH, CF3, C1-C4-alkilen-C1-C4-alkiloksi,
-O-COC1-C4-alkil, OCOC1-C4-alkil-halogen, -O-COCF3 ili halogen,
opcionalno u obliku njihovih pojedinačnih optičkih izomera, mješavina od njihovih pojedinačnih enantiomera ili racemata,
dok, u slučaju da A označava
tada R1 i R2 označavaju metil i
R3, R4, R5 i R6 označavaju vodik,
a R7 ne može biti također vodik,
poželjno, LAMA je spoj formule (LAMA 1):
3. Dugodjelujući muskarinski antagonist (LAMA) ili njegova farmaceutski prihvatljiva sol od kationa, ili farmaceutski pripravak koji sadrži LAMA ili njegovu farmaceutski prihvatljivu sol od kationa, naznačen time, da se u kombinaciji s glukokortikoidom kao što je ciklesonid ili s farmaceutskim pripravkom koji sadrži ciklesonid ili njegovu farmaceutski prihvatljivu sol, upotrebljava u postupku liječenja bolesti dišnih puteva kod jednokopitara, poželjno konja,
pri čemu je LAMA spoj opće formule:
u kojoj
A označava a dvostruko vezanu skupinu odabranu od sljedećih:
X- označava anion s jednostrukim negativnim nabojem;
R1 i R2 označavaju C1-C4-alkil koji može biti opcionalno supstituiran s hidroksi ili halogenom;
R3, R4, R5 i R6, koji mogu biti isti ili različiti, označavaju vodik, C1-C4-alkil,
C1-C4-alkiloksi, hidroksi, CF3, CN, NO2 ili halogen;
R7 označava vodik, C1-C4-alkil, C1-C4-alkiloksi, C1-C4-alkilen-halogen, halogen-C1-C4-alkiloksi, C1-C4-alkilen-OH, CF3, C1-C4-alkilen-C1-C4-alkiloksi,
-O-COC1-C4-alkil, OCOC1-C4-alkil-halogen, -O-COCF3 ili halogen,
opcionalno u obliku njihovih pojedinačnih optičkih izomera, mješavina od njihovih pojedinačnih enantiomera ili racemata,
dok, u slučaju da A označava
tada R1 i R2 označavaju metil i
R3, R4, R5 i R6 označavaju vodik,
a R7 ne može biti također vodik,
poželjno, LAMA je spoj formule (LAMA 1):
4. LAMA za uporabu u skladu s patentnim zahtjevom 2 ili 3, naznačen time, da farmaceutski pripravak je farmaceutski pripravak koji sadrži LAMA ili njegove farmaceutski prihvatljive soli i glukokortikoid kao što je ciklesonid ili budesonid ili njihove farmaceutski prihvatljive soli i opcionalno beta-2-adrenoreceptor-agonist kao što je dugodjelujući beta-2-adrenergijski agonist (LABA – engl. long-acting beta agonist) ili njegove farmaceutski prihvatljive soli te opcionalno jedno farmaceutski prihvatljivo pomoćno sredstvo.
5. LAMA za uporabu u skladu s bilo kojim od patentnih zahtjeva 2 do 4, naznačen time, da su LAMA i glukokortikoid nadalje kombinirani s beta-2-adrenoreceptor-agonistom kao što je dugodjelujući beta-2-adrenergijski agonist (LABA) ili njegove farmaceutski prihvatljive soli.
6. LAMA za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 i 3 do 5, naznačen time, da se kod bolesti dišnih puteva radi o plućnoj bolesti, prvenstveno je bolest dišnih puteva odabrana iz skupine koja se sastoji od sljedećih: periodična opstrukcija dišnih puteva (RAO – engl. recurrent airway obstruction), opstrukcijska plućna bolest povezana s ljetnom ispašom (SPAOPD – engl. summer pasture associated obstructive pulmonary disease) i upalna bolest dišnih puteva (IAD – engl. inflammatory airway disease).
7. LAMA za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time, da se navedeni LAMA ili farmaceutski pripravak koji sadrži LAMA, nalazi u tekućoj formulaciji koja je poželjno djelomično etanolska formulacija, dok navedena tekuća formulacija prvenstveno služi za inhalaciju.
8. LAMA za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time, da se navedeni LAMA ili farmaceutski pripravak koji sadrži LAMA, primjenjuje preko inhalacijskog uređaja (za kopitare), pri čemu navedeni inhalacijski uređaj poželjno obuhvaća:
a. inhalator s odmjerenom dozom pod tlakom ili vodeni/etanolski kapljični inhalator kao što je primjerice Respimat®-inhalator ili neki drugi inhalacijski uređaj koji koristi Respimat®-tehnologiju proizvodnje aerosola, i
b. prilagodnu napravu za primjenu na kopitaru.
9. LAMA za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time, da se LAMA 1 ili njegova farmaceutski prihvatljiva sol od kationa primjenjuje u iznosu jedne doze od 100 µg do 3000 µg izbačene iz inhalatora, od 200 µg do 2000 µg izbačene doze iz inhalatora, od 200 µg do 800 µg izbačene doze iz inhalatora, poželjno u iznosu jedne doze od 200 µg do 800 µg izbačene iz inhalatora.
10. LAMA za uporabu u skladu s bilo kojim od patentnih zahtjeva 2 do 8, naznačen time, da se ciklesonid ili farmaceutski pripravak koji sadrži ciklesonid ili njegovu farmaceutski prihvatljivu sol primjenjuje u iznosu jedne doze od 100 µg do 5000 µg izbačene iz inhalatora, od 450 µg do 3712,5 µg izbačene doze iz inhalatora, od 900 µg do 3712,5 µg izbačene doze iz inhalatora, poželjno u iznosu jedne doze od 900 µg do 3712,5 µg izbačene iz inhalatora.
11. LAMA za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time, da se LAMA ili farmaceutski pripravak koji sadrži LAMA primjenjuje jednom ili dva puta dnevno, poželjno jednom dnevno.
12. LAMA za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time, da se koncentracija LAMA 1 nalazi u rasponu od 0,2 do 7% m/V, još poželjnije od 0,3 do 6,0% m/V ili od 0,4 do 5% m/V od ukupnog sastava pripravka.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14172925 | 2014-06-18 | ||
| PCT/EP2015/063265 WO2015193213A1 (en) | 2014-06-18 | 2015-06-15 | Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses |
| EP15728025.6A EP3157522B1 (en) | 2014-06-18 | 2015-06-15 | Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192010T1 true HRP20192010T1 (hr) | 2020-02-07 |
Family
ID=50972546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192010TT HRP20192010T1 (hr) | 2014-06-18 | 2019-11-06 | Muskarinski antagonisti i njihove kombinacije za liječenje bolesti dišnih puteva kod konja |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9474747B2 (hr) |
| EP (2) | EP3603640A1 (hr) |
| KR (1) | KR102618119B1 (hr) |
| AU (2) | AU2015276310B2 (hr) |
| CA (1) | CA2952701C (hr) |
| CY (1) | CY1122335T1 (hr) |
| DK (1) | DK3157522T3 (hr) |
| ES (1) | ES2759247T3 (hr) |
| HR (1) | HRP20192010T1 (hr) |
| HU (1) | HUE051527T2 (hr) |
| LT (1) | LT3157522T (hr) |
| MX (2) | MX370430B (hr) |
| PL (1) | PL3157522T3 (hr) |
| PT (1) | PT3157522T (hr) |
| RS (1) | RS59613B1 (hr) |
| SI (1) | SI3157522T1 (hr) |
| WO (1) | WO2015193213A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX364652B (es) | 2012-12-21 | 2019-05-03 | Boehringer Ingelheim Vetmedica Gmbh | Formulacion farmaceutica que comprende ciclesonida. |
| RS57740B1 (sr) | 2012-12-21 | 2018-12-31 | Boehringer Ingelheim Vetmedica Gmbh | Ciklezonid za lečenje oboljenja disajnih puteva kod konja |
| SI3157522T1 (sl) | 2014-06-18 | 2020-01-31 | Boehringer Ingelheim Vetmedica Gmbh | Muskarinski antagonisti in njihove kombinacije za zdravljenje bolezni dihalne poti pri konjih |
| CN111840256A (zh) * | 2019-04-29 | 2020-10-30 | 上海谷森医药有限公司 | 一种雾化吸入剂及其制备方法 |
| CN112752572B (zh) | 2019-05-23 | 2022-02-22 | 广州谷森制药有限公司 | 含有三苯乙酸维兰特罗和芜地溴铵的可吸入溶液组合物 |
| US20220031712A1 (en) * | 2020-06-23 | 2022-02-03 | Cai Gu Huang | Preparation of a pharmaceutical composition of olodaterol and budesonide |
| KR20230052903A (ko) | 2020-07-31 | 2023-04-20 | 케모 리서치, 에스.엘. | 흡입 투여를 위한 병용 요법 |
| CN116963715A (zh) | 2020-09-29 | 2023-10-27 | 艾罗克斯医疗有限责任公司 | 茚达特罗的液体配制品 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5954049A (en) | 1991-10-15 | 1999-09-21 | Trudell Medical Limited | Equine mask with MDI adapter |
| DE19536902A1 (de) | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim Int | Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung |
| US5823179A (en) * | 1996-02-13 | 1998-10-20 | 1263152 Ontario Inc. | Nebulizer apparatus and method |
| US6264923B1 (en) | 1998-05-13 | 2001-07-24 | 3M Innovative Properties Company | Medicinal aerosol formulation of ciclesonide and related compounds |
| DE10050994A1 (de) * | 2000-10-14 | 2002-04-18 | Boehringer Ingelheim Pharma | Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung |
| US6706726B2 (en) | 2000-10-14 | 2004-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Anticholinergics which may be used as medicaments as well as processes for preparing them |
| DE10062712A1 (de) | 2000-12-15 | 2002-06-20 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden |
| US6904908B2 (en) * | 2002-05-21 | 2005-06-14 | Trudell Medical International | Visual indicator for an aerosol medication delivery apparatus and system |
| US7244742B2 (en) | 2002-08-17 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic |
| DE10237739A1 (de) * | 2002-08-17 | 2004-02-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika |
| US20040053902A1 (en) * | 2002-09-13 | 2004-03-18 | Smith C. Steven | Novel composition and method for treatment of upper respiratory conditions |
| WO2004103379A1 (en) | 2003-05-22 | 2004-12-02 | Altana Pharma Ag | Salmeterol and ciclesonide combination |
| US20050020692A1 (en) * | 2003-07-24 | 2005-01-27 | Ciofalo Vincent B. | Treatment of heaves |
| PL1670482T5 (pl) | 2003-09-16 | 2022-10-03 | Covis Pharma Gmbh | Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego |
| PE20050941A1 (es) | 2003-12-16 | 2005-11-08 | Nycomed Gmbh | Suspensiones acuosas de ciclesonida para nebulizacion |
| AU2005235384B2 (en) | 2004-04-20 | 2010-09-09 | Covis Pharma B.V. | Use of ciclesonide for the treatment of respiratory diseases in a smoking patient |
| WO2006003078A1 (en) | 2004-06-29 | 2006-01-12 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising steroids and an anticholinergic |
| DE102004056579A1 (de) * | 2004-11-23 | 2006-05-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Arzneimittel enthaltend ein neues Anticholinergikum, Salmeterol und ein Steroid |
| US20070028923A1 (en) | 2005-08-08 | 2007-02-08 | Patrick Souris | Tip-laryngeal airway |
| UY30543A1 (es) | 2006-08-18 | 2008-03-31 | Boehringer Ingelheim Int | Formulacion de aerosol para la inhalacion de beta- agonistas |
| UY30542A1 (es) | 2006-08-18 | 2008-03-31 | Boehringer Ingelheim Int | Formulacion de aerosol para la inhalacion de agonistas beta |
| KR101331324B1 (ko) | 2008-10-30 | 2013-11-20 | 지멘스 악티엔게젤샤프트 | 다중 스탠드 압연 트레인을 통과하는 압연 재료의 배출 두께 조정 방법, 개회로 제어 장치 및/또는 폐회로 제어 장치 및 압연 설비 |
| US8815258B2 (en) * | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| CN104799969B (zh) | 2009-06-25 | 2018-11-06 | 贝林格尔·英格海姆维特梅迪卡有限公司 | 吸入器 |
| WO2014007767A1 (en) * | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dry powder inhalers comprising a carrier other than lactose and a ternary component |
| US20150202148A1 (en) * | 2012-07-05 | 2015-07-23 | Arven llac Sanayi Ve Ticaret Anonim Sirketi | Dry powder inhalers comprising a carrier other than lactose |
| WO2014016548A2 (en) * | 2012-07-27 | 2014-01-30 | Cipla Limited | Pharmaceutical composition |
| US9539408B2 (en) * | 2012-10-31 | 2017-01-10 | Trudell Medical International | Nebulizer apparatus |
| MX364652B (es) * | 2012-12-21 | 2019-05-03 | Boehringer Ingelheim Vetmedica Gmbh | Formulacion farmaceutica que comprende ciclesonida. |
| RS57740B1 (sr) | 2012-12-21 | 2018-12-31 | Boehringer Ingelheim Vetmedica Gmbh | Ciklezonid za lečenje oboljenja disajnih puteva kod konja |
| SI3035886T1 (sl) * | 2013-08-20 | 2021-02-26 | Boehringer Ingelheim Vetmedica Gmbh | Inhalator |
| EP3632373B1 (en) * | 2013-08-20 | 2023-08-09 | Boehringer Ingelheim Vetmedica GmbH | Inhaler |
| SI3157522T1 (sl) | 2014-06-18 | 2020-01-31 | Boehringer Ingelheim Vetmedica Gmbh | Muskarinski antagonisti in njihove kombinacije za zdravljenje bolezni dihalne poti pri konjih |
-
2015
- 2015-06-15 SI SI201531016T patent/SI3157522T1/sl unknown
- 2015-06-15 KR KR1020177001472A patent/KR102618119B1/ko active IP Right Grant
- 2015-06-15 RS RS20191483A patent/RS59613B1/sr unknown
- 2015-06-15 PT PT157280256T patent/PT3157522T/pt unknown
- 2015-06-15 AU AU2015276310A patent/AU2015276310B2/en active Active
- 2015-06-15 ES ES15728025T patent/ES2759247T3/es active Active
- 2015-06-15 EP EP19192103.0A patent/EP3603640A1/en active Pending
- 2015-06-15 EP EP15728025.6A patent/EP3157522B1/en active Active
- 2015-06-15 HU HUE15728025A patent/HUE051527T2/hu unknown
- 2015-06-15 WO PCT/EP2015/063265 patent/WO2015193213A1/en active Application Filing
- 2015-06-15 LT LT15728025T patent/LT3157522T/lt unknown
- 2015-06-15 MX MX2016016720A patent/MX370430B/es active IP Right Grant
- 2015-06-15 CA CA2952701A patent/CA2952701C/en active Active
- 2015-06-15 DK DK15728025T patent/DK3157522T3/da active
- 2015-06-15 PL PL15728025T patent/PL3157522T3/pl unknown
- 2015-06-16 US US14/740,582 patent/US9474747B2/en active Active
-
2016
- 2016-09-23 US US15/274,259 patent/US10342789B2/en active Active
- 2016-12-15 MX MX2019014935A patent/MX2019014935A/es unknown
-
2019
- 2019-05-08 US US16/406,918 patent/US10682345B2/en active Active
- 2019-11-06 HR HRP20192010TT patent/HRP20192010T1/hr unknown
- 2019-12-02 CY CY20191101258T patent/CY1122335T1/el unknown
-
2020
- 2020-04-06 AU AU2020202402A patent/AU2020202402B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3157522A1 (en) | 2017-04-26 |
| PT3157522T (pt) | 2019-12-13 |
| RS59613B1 (sr) | 2020-01-31 |
| SI3157522T1 (sl) | 2020-01-31 |
| WO2015193213A1 (en) | 2015-12-23 |
| US10682345B2 (en) | 2020-06-16 |
| US10342789B2 (en) | 2019-07-09 |
| US20150366855A1 (en) | 2015-12-24 |
| LT3157522T (lt) | 2019-11-25 |
| KR20170016986A (ko) | 2017-02-14 |
| CA2952701C (en) | 2023-09-19 |
| PL3157522T3 (pl) | 2020-03-31 |
| EP3157522B1 (en) | 2019-09-04 |
| MX2019014935A (es) | 2020-02-13 |
| HUE051527T2 (hu) | 2021-03-01 |
| AU2020202402B2 (en) | 2021-05-27 |
| AU2015276310A1 (en) | 2016-12-08 |
| US20190262329A1 (en) | 2019-08-29 |
| MX2016016720A (es) | 2017-04-13 |
| KR102618119B1 (ko) | 2023-12-27 |
| EP3603640A1 (en) | 2020-02-05 |
| DK3157522T3 (da) | 2019-12-09 |
| MX370430B (es) | 2019-12-13 |
| AU2015276310B2 (en) | 2020-01-16 |
| US9474747B2 (en) | 2016-10-25 |
| AU2020202402A1 (en) | 2020-04-30 |
| CA2952701A1 (en) | 2015-12-23 |
| ES2759247T3 (es) | 2020-05-08 |
| US20170007593A1 (en) | 2017-01-12 |
| CY1122335T1 (el) | 2021-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192010T1 (hr) | Muskarinski antagonisti i njihove kombinacije za liječenje bolesti dišnih puteva kod konja | |
| HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
| HRP20201435T1 (hr) | Spojevi koji imaju aktivnost kao antagonist muskarinskog receptora i kao agonist beta2 adrenergijskog receptora | |
| EP2948148B1 (en) | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide | |
| JP6099609B2 (ja) | 肺炎症を低減するためのレボフロキサシンの吸入 | |
| AR076621A1 (es) | Composiciones para el suministro de antagonistas muscarinicos de accion prolongada y agonista del receptor adrenergico b2 de accion prolongada. metodo de tratamiento. sistemas asociados. inhalador dosificador | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
| JP2011162556A5 (hr) | ||
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BR112015014222A2 (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de anemia e composição farmacêutica | |
| BR112015029401A2 (pt) | derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| RU2018135967A (ru) | Интраназальные фармацевтические композиции на основе бензодиазепина | |
| JP2016527220A5 (hr) | ||
| CL2018003391A1 (es) | Beta-horquilla peptidomimética con actividad inhibidora de elastasa y formas de dosificación en aerosol de la misma. | |
| HRP20161389T1 (hr) | Derivati pantotenata namijenjeni liječenju neuroloških poremećaja | |
| ES2610104T3 (es) | Aclidinio para el uso en la mejora de la calidad del sueño en pacientes con enfermedades respiratorias | |
| HRP20210640T1 (hr) | Kombinacija čistih 5-ht6 antagonista receptora sa nmda antagonistom receptora | |
| HRP20201412T1 (hr) | Trostruka kombinacija čistih antagonista receptora 5-ht6, inhibitora acetilkolinesteraze i antagonista receptora nmda | |
| JP2015522544A5 (hr) | ||
| JP2011500731A5 (hr) | ||
| HRP20200432T1 (hr) | Oblik za kombinacijsko doziranje antagonista mu opioidnog receptora i opioidnog sredstva | |
| JP2010538010A5 (hr) | ||
| JP2013519695A5 (hr) | ||
| JP2016538288A5 (hr) |